Stereotactic body radiotherapy for oligometastatic soft tissue sarcoma

Area of Science:

• Oncology
• Radiation Oncology

Background:

• Stereotactic body radiotherapy (SBRT) is an emerging treatment for metastatic soft tissue sarcoma (STS).
• Evaluating SBRT's efficacy in oligometastatic STS (≤3 synchronous lesions) is crucial.

Purpose of the Study:

• To assess the effectiveness of exclusive SBRT in controlling disease and improving survival in patients with oligometastatic STS.
• To identify predictors of treatment outcomes in this patient population.

Main Methods:

• Retrospective analysis of 16 patients with oligometastatic STS treated with SBRT.
• Assessed local control (LC), overall survival (OS), distant metastases-free survival (DMFS), and corrected disease-free survival (cDFS).
• Collected patient and treatment characteristics, including time from primary tumor treatment to first metastasis.

Main Results:

• Four-year OS was 54% (median 69 months); 4-year LC was 78%.
• Median DMFS was 17 months and median cDFS was 28 months.
• Disease-free interval < 24 months was the only predictor of reduced LC, cDFS, and OS (p < 0.05). No grade ≥3 toxicity observed.

Conclusions:

• Exclusive SBRT provides satisfying local control and minimal toxicity in oligometastatic STS.
• Median OS was 69 months; repeated SBRT may extend disease-free intervals.
• A longer disease-free interval from primary tumor to first metastasis indicates patients who may benefit more from SBRT.